$44.86
3.24%
Nasdaq, Nov 17, 03:59 pm EST. Closed.
ISIN
US74587B1017
Symbol
PLSE

Pulse Biosciences, Inc. Stock price

$46.36
+1.93 4.34% 1M
+20.75 81.02% 6M
+32.63 237.65% YTD
+32.61 237.16% 1Y
+40.12 642.95% 3Y
+24.78 114.83% 5Y
+40.41 679.17% 10Y
+42.19 1,011.75% 20Y
Nasdaq, Closing price Mon, Nov 16 2026
-4.08 8.09%

Is Pulse Biosciences, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,087 stocks worldwide.

Key metrics

Basic
Market capitalization
$3.4b
Enterprise Value
$3.3b
Net debt
positive
Cash
$101.6m
Shares outstanding
70.8m
Valuation
P/E
negative
P/S | estimate
2,865.3 | 1,716.9
EV/Sales | estimate
2,779.9 | 1,665.7
EV/FCF | ex SBC
negative | negative
P/B
34.3
Financial Health
Equity Ratio
85.3%
Return on Equity
-90.2%
ROCE
-79.4%
ROIC
-
Debt/Equity
0.0
Share-Based Compensation & Dilution
SBC | % of Revenue
$17.5m | 1,468.1%
SBC as % of FCF
-
SBC Growth 1Y
-15.4%
Share Count Growth 1Y
5.2%
Shareholder Yield
-5.2%
Financials
Revenue | estimate
$1.2m | $2.0m
EBITDA
$-82.0m
EBIT
$-83.0m
Net Income
$-80.1m
Free Cash Flow | ex SBC
$-61.4m | $-78.9m
Growth
Revenue | estimate
- | 467.4%
EBITDA
-15.4%
EBIT
-15.0%
Net Income
-17.7%
Free Cash Flow
-37.2%
Margin
Gross
0.3%
EBITDA
-6,921.4%
EBIT
-7,007.8%
Net
-6,755.8%
Free Cash Flow | ex SBC
-5,180.4% | -6,654.9%
More
EPS
$-1.2
FCF per Share
$-0.9
Short interest
12.4%
Employees
116
Rev per Employee
$0.0

Pulse Biosciences, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Pulse Biosciences, Inc. forecast:

11x Buy
92%
1x Hold
8%

Analyst Opinions

12 Analysts have issued a Pulse Biosciences, Inc. forecast:

Buy
92%
Hold
8%

Pulse Biosciences, Inc. Events

Past Events
NOV
5
Q3 2026 Earnings Call
12 days ago
AUG
6
Q2 2026 Earnings Call
3 months ago
JUN
10
Goldman Sachs 47th Annual Global Healthcare Conference 2026
5 months ago
MAY
13
Bank of America Global Healthcare Conference 2026
6 months ago
MAY
7
Q1 2026 Earnings Call
6 months ago
APR
25
Shareholder/Analyst Call - Pulse Biosciences, Inc.
7 months ago
FEB
19
Q4 2025 Earnings Call
9 months ago
JAN
14
44th Annual J.P. Morgan Healthcare Conference
10 months ago
NOV
5
Q3 2025 Earnings Call
about one year ago

Financial data from Pulse Biosciences, Inc.

Jun '26
+/-
%
1.19 1.19
-
100%
- Direct Costs 1.18 1.18
-
99%
- -
-
-
- Selling and Administrative Expenses 29 29
3% 3%
2,408%
- Research and Development Expense 52 52
27% 27%
4,361%
-82 -82
15% 15%
-6,892%
- Depreciation and Amortization 1.02 1.02
11% 11%
86%
EBIT (Operating Income) EBIT -83 -83
15% 15%
-6,978%
Net Profit -80 -80
18% 18%
-6,728%

In millions USD.

Don't miss a Thing! We will send you all news about Pulse Biosciences, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Pulse Biosciences, Inc. Stock News

Neutral
Business Wire
●
11 days ago
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), the company leveraging its ever evolving novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced interim six-month results from PRECISE-BTN, a prospective, multicenter U.S. study evaluating the nPulse™ Vybrance™ Percutaneous Electrode System for the treatment of symptomatic...
Neutral
Business Wire
●
12 days ago
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), the company leveraging its ever evolving novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced business updates and financial results for the third quarter ended September 30, 2026. “Pulse Biosciences delivered several major milestones since the second quarter, led by com...
More Pulse Biosciences, Inc. News

Company Profile

Pulse Biosciences, Inc. operates as an immuno-oncology company developing a proprietary oncolytic electroceutical therapy based on its Nano Pulse Stimulation (NPS) technology. It manufactures surgical and medical instruments uses a novel and proprietary platform technology called Nano-Pulse Electro-Signaling. The NPES provides local tumor control and initiates an adaptive immune response with a vaccine-like effect by inducing immunogenic apoptosis of the cells. The company was founded on May 19, 2014 and is headquartered in Hayward, CA.

Head office United States
CEO Mr. Laviolette
Employees 116
Founded 2014
Website www.pulsebiosciences.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today